Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Recent & Breaking News (OTCQX:CSLLY)

CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit

PR Newswire June 12, 2020

CSL Behring to Acquire Biotech Company Vitaeris

PR Newswire June 8, 2020

CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema

PR Newswire June 8, 2020

The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate

PR Newswire June 5, 2020

CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases

PR Newswire June 2, 2020

Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services

PR Newswire May 27, 2020

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

PR Newswire May 26, 2020

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

PR Newswire May 7, 2020

CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)

PR Newswire April 21, 2020

CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

PR Newswire April 8, 2020

Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older

PR Newswire February 24, 2020

University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware

PR Newswire February 13, 2020

PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)

PR Newswire February 11, 2020

Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

PR Newswire February 3, 2020

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

PR Newswire January 24, 2020

Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity

PR Newswire January 21, 2020

Researchers decipher a new way that immune cells detect infections and cancers

PR Newswire January 10, 2020

Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference

PR Newswire January 9, 2020

Harvard Business Review Names CSL's Paul Perreault Among Best Performing CEOs in the World

PR Newswire October 24, 2019

Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats

PR Newswire September 26, 2019